 Home > Active Ingredient News > Antitumor Therapy > J Clin Oncol: Rituximab + Lenalidomide + Ibrutinib in Newly Diagnosed Diffuse Large B-Cell Lymphoma

J Clin Oncol: Rituximab + Lenalidomide + Ibrutinib in Newly Diagnosed Diffuse Large B-Cell Lymphoma

 Last Update: 2022-08-19
 Source: Internet
 Author: User

Tags

large quantity

journal 29

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Chemoimmunotherapy for patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) has remained largely unchanged for decade.

The study was designed to evaluate the efficacy and safety of the combination of rituximab, lenalidomide, and ibrutinib in newly diagnosed diffuse large B-cell lymphom.

This is an investigator-initiated, single-arm, Phase 2 clinical trial that enrolled 60 patients with newly diagnosed non-germinal center B-cell-like DLBCL to receive rituximab (375 mg/m2, day 1) , lenalidomide (25 mg/day, days 1-10) and ibrutinib (560 mg/day) (RLI) were treated sequentially, with 21 days as a course of treatmen.

The median age of patients tested was 65 years (range, 29-83 years), and 28% of patients were 70 years or olde.

It is understood that this study is the first clinical study of targeted therapy for newly diagnosed DLBCL before chemotherap.

Original source:

Jason Westin, et a.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Crocetin27876-94-4

CAS No.: 27876-94-4

$1-1.1/G FOB

Betulinic acid472-15-1

CAS No.: 472-15-1

$1-1.1/G FOB

1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane 53-19-0

CAS No.: 53-19-0

Pharmacy Grade

$100/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.